Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Amphastar Pharmaceuticals, Inc. - Common Stock
(NQ:
AMPH
)
27.47
-0.15 (-0.54%)
Streaming Delayed Price
Updated: 3:34 PM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amphastar Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest
February 19, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
NASDAQ:AMPH is an undervalued gem with solid fundamentals.
↗
February 18, 2025
AMPHASTAR PHARMACEUTICALS IN is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:AMPH showcases decent financial health and profitability, coupled with an attractive price.
Via
Chartmill
Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks
February 14, 2025
Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group
February 13, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024
November 06, 2024
Via
ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024
August 07, 2024
Via
ACCESSWIRE
Why the growth investor may take a look at NASDAQ:AMPH.
↗
June 05, 2024
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) may be suited for growth investing, we'll explore why in this article.
Via
Chartmill
Earnings Scheduled For February 27, 2025
↗
February 27, 2025
Via
Benzinga
Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow
February 26, 2025
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.
Via
StockStory
Top 2 Health Care Stocks That May Rocket Higher This Month
↗
February 21, 2025
Via
Benzinga
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks
February 21, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025
February 20, 2025
Via
ACCESS Newswire
Exploring NASDAQ:AMPH's growth characteristics.
↗
May 15, 2024
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations
Via
Chartmill
This Ollie's Bargain Outlet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
↗
February 04, 2025
Via
Benzinga
Investors should take notice of NASDAQ:AMPH—it offers a great deal for the fundamentals it presents.
↗
January 27, 2025
AMPHASTAR PHARMACEUTICALS IN has caught the attention as a great value stock. NASDAQ:AMPH excels in profitability, solvency, and liquidity, all while being very reasonably priced.
Via
Chartmill
Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025
Via
ACCESSWIRE
NASDAQ:AMPH is an undervalued gem with solid fundamentals.
↗
January 06, 2025
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference
November 26, 2024
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
November 13, 2024
Via
ACCESSWIRE
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
↗
October 15, 2024
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
Via
Investor's Business Daily
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
↗
September 06, 2024
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris.
Via
Benzinga
Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
August 28, 2024
Via
ACCESSWIRE
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024
↗
August 07, 2024
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024
July 31, 2024
Via
ACCESSWIRE
7 Biotech Stocks to Buy on the Dip: June 2024
↗
June 24, 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Via
InvestorPlace
Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts
June 18, 2024
These 2 small cap healthcare stocks could boom on a new sector breakout, Wall Street analysts see up to double-digit upside in each
Via
MarketBeat
Topics
ETFs
Economy
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
June 04, 2024
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
June 03, 2024
Via
ACCESSWIRE
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
May 22, 2024
Via
ACCESSWIRE
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
↗
May 16, 2024
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
Via
InvestorPlace
Topics
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
